Takashi Kumagai
Toho University(JP)Toho University Omori Medical Center(JP)
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, Eosinophilic Disorders and Syndromes, Lymphoma Diagnosis and Treatment, Multiple Myeloma Research and Treatments
Most-Cited Works
- → Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial(2015)300 cited
- → Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment(2018)117 cited
- → Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial(2020)101 cited
- → Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation(2017)65 cited
- → Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial(2021)61 cited
- → Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group